The Latest Vaccine News

According to Datamonitor Healthcare, it performs better than other traditional inactivated flu vaccines, meaning that in its expected launch for the 2020-2021 flu season it could capture a large part of the elderly population. First approved in 2000, Prevnar 7 was the first pneumococcal conjugate va...

Full description

Saved in:
Bibliographic Details
Published in:Managed Healthcare Executive 2019-06, Vol.29 (6), p.24-26
Main Author: Hamm, Nicholas
Format: Article
Language:English
Subjects:
Antibiotics
Cell culture
Disease
FDA approval
Immunization
Influenza
Older people
Seasons
Vaccines
Viruses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to Datamonitor Healthcare, it performs better than other traditional inactivated flu vaccines, meaning that in its expected launch for the 2020-2021 flu season it could capture a large part of the elderly population. First approved in 2000, Prevnar 7 was the first pneumococcal conjugate vaccine. According to Datamonitor Healthcare, it could replace Prevnar 13 on its expected approval in 2022-if it proves superior to Pfizer's drug and if serotype drift occurs. According to Datamonitor Healthcare, it could achieve this due to its broad serotype coverage-it would be the first vaccine cover serotypes A, B, C, W, and Y, which could allow it to cover a wide range of patient populations.
ISSN:1533-9300
2150-7120